NONPOLAR OLIGOSACCHARIDE CONGENER BINDING TO PROTEINS

寡糖-蛋白质结合涉及几个过程 包括免疫相关反应、病原体侵袭和肿瘤 转移 碳水化合物结合抑制剂可能导致治疗 这些疾病状态。 抑制剂的形成已被 结构修饰的复合糖的不可用性，并继续 由于缺乏对结构的详细了解， 碳水化合物的特性很重要，以及它们如何影响结合 在分子水平上。 这里提出的研究重点是抑制蛋白质- 碳水化合物识别，以提供对结合的见解， 过程和合理的方法来开发有效的治疗方法。 的 待探测的系统是人乳腺肿瘤抗原的结合， globo-H，与单克隆抗体MBr 1。 教授的开创性工作。 纪念斯隆-凯特琳的丹尼舍夫斯基允许进入 和修饰的寡糖。因此，聚焦的主要优点 在这个系统上，两种合成路线都能产生潜在的 抑制剂和检测方法，以评估他们的地方，快速 朝着研究目标前进。

Oligosaccharide-protein binding is implicated in several processes including immune related responses, pathogenic invasion and tumor metastasis. Carbohydrate binding inhibitors could lead to therapies for these disease states. Inhibitor development has been slowed by the unavailability of structrually modified complex sugars and continue to be hampered by a lack of detailed understanding of which structural features of the carbohydrate are important and how they affect binding at the molecular level. The studies proposed here focus on the inhibition of protein- carbohydrate recognition to provide both insights into the binding process and a rational approach to develop effective treatments. The system to be probed is the binding of a human breast tumor antigen, globo-H, to monoclonal antibody MBr1. The pioneering work of Prof. Danishefsky at Memorial Sloan-Kettering has allowed access to complex and modified oligosaccharides. Thus, the major advantages of focusing on this system are that both synthetic routes to generate potential inhibitors and assays to evaluate them are in place for rapid advancement toward the research goals.